Recommendations for reporting morbid events after heart valve surgery

Journal of Heart Valve Disease

Volumn 14, Issue 1, 2005, Pages 1-7

  Horstkotte, Dieter ^a   Lengyel, Maria ^b   Mistiaen, Wilhelm P ^c   Piper, Cornelia ^a   Völler, Heinz ^d  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Hungarian Institute of Cardiology   (Hungary)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d Klinik am See   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ANTICOAGULANT THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; BLEEDING; BLOOD TRANSFUSION; CLINICAL FEATURE; CLINICAL RESEARCH; COMORBIDITY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DATA ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DRUG MONITORING; EMBOLISM; FOLLOW UP; HEART FUNCTION; HEART VALVE PROSTHESIS; HEART VALVE SURGERY; HOSPITAL ADMISSION; HOSPITAL CARE; HUMAN; IMAGING SYSTEM; INTRAVASCULAR HEMOLYSIS; MEDICAL CARE; OUTCOME ASSESSMENT; PATIENT PARTICIPATION; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSTHESIS FAILURE; SCORING SYSTEM; SELF REPORT; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; CLINICAL TRIAL; DOCUMENTATION; HEALTH STATUS; INFORMATION PROCESSING; PATIENT SELECTION; PRACTICE GUIDELINE; STANDARD; STATISTICAL ANALYSIS; VALVULAR HEART DISEASE;

ANTICOAGULANTS; CLINICAL TRIALS; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; DOCUMENTATION; HEALTH STATUS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS; HUMANS; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; PROSTHESIS FAILURE;

EID: 17944365590     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Horstkotte D. Problems with complication rate analysis. J Thorac Cardiovasc Surg 2003;126:1668-1669
2. Bergemann R, Hillenback C. Addendum. Eur Heart J Suppl 2001;3(Suppl.Q):Q78-Q79
3. Horstkotte D, Schulte H, Bircks W, Strauer B. Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10 year follow-up of patients with St. Jude Medical prostheses. J Heart Valve Dis 1993;2:291-301
4. Edmunds LH, Jr., Clark RE, Cohn LH, Grunkemeier GL, Miller DC, Weisel RD. Guidelines for reporting morbidity and mortality after cardiac valvular operations. J Thorac Cardiovasc Surg 1996;112:708-711
5. Grunkemeier GL, Wu XY. Our complication rates are lower than theirs: Statistical critique of heart valve comparisons. J Thorac Cardiovasc Surg 2003;125:290-300
6. Horstkotte D, Trampisch JH. Long-term follow-up after heart valve replacement. Z Kardiol 1986;75:641-645
7. Altman DG. Practical Statistics for Medical Research. 1st edn. Chapman & Hall, London, 1991:81
8. Elwood M. Critical Appraisal of Epidemiologic Studies and Clinical Trials. 2nd edn. Oxford University Press, 1998:84-85, 145-150
9. Horstkotte D, Hering D, Faber L, Piper C. Cardiac morphology and physiology predisposing to thrombus formation. Eur Heart J Suppl 2001;3(Suppl.Q):Q8-Q11
10. Hering D, Piper C, Horstkotte D. Influence of atypical symptoms and electrocardiographic signs of left ventricular hypertrophy or ST-segment/T-wave abnormalities on the natural history of otherwise asymptomatic adults with moderate to severe aortic stenosis: Preliminary communication. J Heart Valve Dis 2004;13:182-187
11. Pardaens K, von Cleemput J, Vanhaecke J, Fagard RH. Peak oxygen consumption better predicts outcome than submaximal respiratory data in transplant candidates. Circulation 2000;101:1152-1157
12. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370
13. Bodnar E, Horstkotte D. Potential flaws in the assessment of minor cerebrovascular events after heart valve replacement. J Heart Valve Dis 1993;2:287-290
14. Horstkotte D, Bergemann R, Althaus U, et al. German Experience with Low Intensity Anticoagulation (GELIA): Protocol of a multi-center randomized prospective study with the St. Jude Medical valve. J Heart Valve Dis 1993;2:411-419
15. Salem DN, Stein PD, Al-Ahmad A. Seventh ACCP Consensus Conference on Antithrombotic Therapy. Antithrombotic Therapy in Valvular Heart Disease: Native and Prosthetic. Chest 2004;126(Suppl.):457S-482S
16. Pruefer D, Dahm M, Dohmen, Horstkotte D, Bergemann R, Oelert H. Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: Lessons learned from GELIA (GELIA 5). Eur Heart J Suppl 2001;3(Suppl.Q):Q33-Q38
17. Blackstone EH, Naftel DC, Turner ME, Jr. The decomposition of time-varying hazard into phases, each incorporating a separate stream of concomitant information. J Am Statist Assoc 1996;81:615-624
18. Karnofsky DA, Burchenai JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLoad CM (ed.), Symposium held at New York Academy of Medicine. Columbia University Press, 1949:191-205
19. Lengyel M, Vándor L. The role of thrombolysis in the management of left-sided prosthetic valve thrombosis: A study of 82 cases diagnosed by transesophageal echocardiography. J Heart Valve Dis 2001;10:646-649
20. Piper C, Hering D, Horstkotte D. Prosthetic valve thrombosis: Predisposition and diagnosis. Eur Heart J Suppl 2001;3(Suppl.Q):Q16-Q22
21. Piper C, Hering D, Langer C, Horstkotte D. Inappropriate reporting of morbid events following mechanical heart valve replacement: A prospective study of patients presenting with stroke. Eur Heart J 2004;25(Abstr Suppl):657
22. Cannegieter SC, Roosendaal FR, Wintzen A, et al. Optimal anticoagulation for non rheumatic atrial fibrillation. N Engl J Med 1995;333:11-17
23. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598-603
24. Motto C, Aritzu E, Boccardi E, et al. Reliability of hemorrhagic transformation diagnosis in acute ischemic stroke. Stroke 1997;28:302-306
25. Horstkotte D, on behalf of the Task Force of Infective Endocarditis of the European Society of Cardiology. Guidelines on Prevention, Diagnosis and Treatment of Infective Endocarditis. Eur Heart J 2004;25:267-276
26. Horstkotte D, Piper C, Wiemer M, Schultheiß HP. Management of patients with aortic valve stenosis. Herz 1998;23:434-440
27. Horstkotte D Haerten K, Seipel L, et al. Central hemodynamics. Circulation 1983;68(Suppl.II):II161-II168
28. Butany J, Yu W, Silver MD, David TE. Morphologic findings in explanted Hancock II porcine bioprostheses. J Heart Valve Dis 1999;8:4-15
29. Bottio T, Thiene G, Pettenazzo E, et al. Hancock II bioprosthesis: A glance at the microscope in mid-long-term explants. J Thorac Cardiovasc Surg 2003;126:99-105
30. Jamieson WR, Rosado LJ, Munro Al, et al. Carpentier-Edwards standard porcine bioprosthesis: Primary tissue failure (structural valve deterioration) by age groups. Ann Thorac Surg 1988;46:155-162
31. Takkenberg JJ, van Herwerden LA, Eikemans MJ, Bekkers JA, Bogers AJJ. Evolution of allograft aortic valve replacement over 13 years: Results of 275 procedures. Eur J Cardiothorac Surg 2002;21:683-691
32. Horstkotte D, Aul C, Seipel L, et al. Effect of valve type and valve function on chronic intravascular hemolysis after alloprosthetic mitral and aortic valve replacement. Z Kardiol 1983;72:119-131
33. Piper C, Horstkotte D. State of the art: Anticoagulation management. J Heart Valve Dis 2004;13(Suppl.1):S76-S80
34. Hering D, Piper C, Bergemann R, et al. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: Results of the German Experience with Low Intensity Anticoagulation (GELIA) study (GELIA 10). Chest 2005;127:53-59
35. Acar J, Iung B, Boissel JP, et al. AREVA: Multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 1996;94:2107-2112
36. Meschengieser SS, Fondevila CG, Frontroth J, et al. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: A randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg 1997;113:910-916
37. Horstkotte D, Bergemann R, for the GELIA Study Investigator Group. Antithrombotic management after heart valve replacement: Results and consequences of the GELIA study. Eur Heart J 2001;3(Suppl.Q):Q1-Q79
38. Koertke H, Koerfer R. International normalized ratio self-management after mechanical heart valve replacement: Is an early start advantageous? Ann Thorac Surg 2001;72:44-48
39. Hirsh J, Fuster V, Ansell J, Jonathan LH. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation 2003;107:1692-1711